Investor Presentation

8 X Broad Applicability of Expanded Corbus Pipeline Lenabasum Preferential CB2 agonist Peripheral preference TARGETED INDICATIONS Systemic Sclerosis (Phase 3) Dermatomyositis (Phase 3) Lupus (Phase 2) Cystic Fibrosis (Phase 2) ● ● Projected Launch 2021 CRB-4001 2nd Gen CB1 inverse agonist Peripherally-restricted POTENTIAL INDICATIONS NASH Primary biliary cholangitis Idiopathic pulmonary fibrosis • Radiation-induced pulmonary fibrosis • Myocardial fibrosis • Interstitial nephritis ● ● Significant Market Opportunity Phase 1 Targeting 2019

View entire presentation